CYP2C19 and coronary artery disorder: In patients with stable coronary heart disease, CYP2C19*2 heterozygous carriers taking 225 mg of clopidogrel per day were shown to achieve the same antiplatelet effect with CYP2C19 wild-type patients taking 75 mg of clopidogrel per day.